Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016;388:2039–52.
1. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039–52.
2. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2012;9:13–23.
3. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12: 223.
4. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012; 8: 610–21.
5. Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricemia and gout. Rheumatology (Oxford) 2016 Aug 7 (Epub ahead of print).
6. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277–81.
7. Caspi D, Lubart E, Graff E, Habot B, Yaron M et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103–8
8. Zhang Y, Chen C, Choi H, Chaisson C, Hunter D et al. Purine-rich foods intake and re-current gout attacks. Ann Rheum Dis. 2012;71:1448–53.
9. McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol. 2012;8:173–81.
10. Qaseem A, McLean RM, Starkey M, Forciea MA. Clinical Guidelines Committee of the American College of Physicians. Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017;166:52–57.
11. Pascual E, Batlle-Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis for di-agnosis of intercritical gout. Ann Intern Med. 1999;131:756–9.
12. Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP et al. Serum urate in chronic gout - will it be the first validated soluble biomarker in rheumatology? J Rheumatol. 2011;38:1462–6.
13. Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y et al. The inflammatory pro-cess in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29:1950–3.
14. Howard RG, Pillinger MH, Gyftopoulos S, Thiele RG, Swearingen CJ et al. Reproducibil-ity of musculoskeletal ultrasound for determining monosodium urate deposition: concord-ance between readers. Arthritis Care Res. 2011;63:1456–62.
15. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009;68:1609–12.
16. Glazebrook KN, Guimarães LS, Murthy NS, Black DF, Bongartz T et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24.
17. Araujo EG, Manger B, Perez-Ruiz F, Thiele RG. Imaging of gout: New tools and bi-omarkers? Best Pract Res Clin Rheumatol.
2016;30:638–52.
18. Omoumi P, Zufferey P, Malghem J, So A. Imaging in Gout and Other Crystal-Related Arthropathies. Rheum Dis Clin North Am. 2016;42:621–44.
19. Wilson L, Saseen JJ. Gouty Arthritis: A Review of Acute Management and Prevention. Pharmacotherapy. 2016;36:906–22.
20. Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O’Hanlon CE et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166:37–51.
21. Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American Col-lege of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guide-line From the American College of Physicians. Ann Intern Med. 2017;166:58–68.
22. Richette P, Doherty M, Pascual E, Barskova V, Becce F et al. 2016 updated EULAR evi-dence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42.
23. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M et al. British Society for Rheu-matology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372–4.
24. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431–46.
25. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854–60.
26. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8.
27. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.
28. Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;53:1920–6.
29. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447–61.
30. Beyl RN Jr, Hughes L, Morgan S. Update on Importance of Diet in Gout. Am J Med. 2016;129:1153–8.
31. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and pro-tein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093–103.
32. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: pro-spective cohort study. BMJ. 2008;336:309–12.
33. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 2007;56:2049–55.
34. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:d8190.
35. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL et al. Comparative ef-fects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperu-ricaemia and gout. J Hypertens. 2001;19:1855–60.
36. Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin North Am. 2014;40:375–87.
37. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.
38. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creat-inine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–50.
39. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529–36.
40. Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412–21.
41. Keenan RT. Safety of urate-lowering therapies: managing the risks to gain the benefits. Rheum Dis Clin North Am. 2012;38:663–80.
42. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford). 2003;42:321–5.
43. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med. 2009;169:502–7.
44. De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken). 2014;66:1551–9.
45. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH et al. Long-term cardiovascu-lar mortality among middle-aged men with gout. Arch Intern Med. 2008;168:1104–10.
46. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheuma-tology (Oxford). 2013;52:34–44.